Proton therapy for treating gynecologic cancer after surgery
Official title: Adjuvant Proton Whole Pelvis Radiation Therapy for Treatment of Post-Surgical Gynecologic Cancers
Run by Abramson Cancer Center at Penn Medicine · NCT05758688 · Data updated 2026-11-12
This study is testing a new type of radiation therapy after surgery to see if it helps women with cervical and endometrial cancer while causing fewer side effects.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 25 (estimated) |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Drugs / interventions | radiation |
| Locations | 3 sites (Voorhees Township, New Jersey and 2 other locations) |
| Status | Recruiting |
| Started | November 6, 2023 |
| Main results expected | November 2026 |
| Study ends | December 2026 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT05758688 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with histologically confirmed cervical or endometrial cancer who require adjuvant whole pelvic radiation therapy.
✕Probably not a fit
Patients with prior pelvic radiation, metastatic disease outside the pelvis, or active inflammatory bowel disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase II, single-arm study evaluates the use of Whole Pelvis Pencil Beam Scanning Proton Radiation (PBS PRT) as a post-surgical treatment for patients with gynecologic cancers, specifically cervical and endometrial cancer. The study aims to assess the rate of acute gastrointestinal toxicity associated with this radiation therapy in the adjuvant setting. Conducted at multiple Penn proton centers in the Philadelphia, Lancaster, and South New Jersey areas, patients will receive radiation doses of either 45 or 50.4 Gy in daily fractions. The goal is to improve treatment outcomes while minimizing side effects.
Why it matters
Potential benefit: If successful, this treatment could reduce gastrointestinal toxicity while effectively managing gynecologic cancers post-surgery.
How similar studies have gone: Other studies using proton therapy for cancer treatment have shown promising results, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed cervical or endometrial cancer * Indication for adjuvant whole pelvic radiation therapy, with or without systemic therapy * Age of 18 years or older * Written informed consent * ECOG of 0-2 within 3 months of enrolling Exclusion Criteria: * Prior course of pelvic radiation * Metastatic disease outside of the pelvis * Active inflammatory bowel disease * Incapacity to provide informed consent
Where it's running
-
Virtua Health
Voorhees Township, New Jersey, United States Recruiting -
Lancaster General Health - Ann B. Barshinger Cancer Institute
Lancaster, Pennsylvania, United States Recruiting -
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Neil K Taunk, MD, MSCTS — University of Pennsylvania
- Study coordinator: Project Manager
- Email: RadOncCRU@PennMedicine.upenn.edu
- Phone: 215-662-3790
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Using Belzutifan to treat recurrent clear cell ovarian carcinoma
This study is testing if a new targeted therapy called Belzutifan can help people with recurrent clear cell ovarian cancer feel better and manage their disease.
-
Comparing two types of sutures for vaginal cuff closure in laparoscopic hysterectomy
This study is testing whether a new type of suture can close the vaginal cuff faster than a standard suture for women having laparoscopic hysterectomy, without causing more complications.
-
Testing Rinatabart Sesutecan for advanced solid tumors
This study is testing a new drug called Rinatabart Sesutecan to see if it can safely help people with advanced solid tumors, like certain types of ovarian and endometrial cancers.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.